Safety and Effectiveness of the CLEAR + BRILLIANT TOUCH(R) Diode Laser 1440-nm and 1927-nm Combination Wavelength Treatment

Exclusion Criteria

• •1\. Pregnant, breastfeeding, or planning to become pregnant during the study. 2 History of any type of allergic reaction to lidocaine. 3. Recent and/or active localized or systemic infections. 4. Diagnosis/possibility of actinic keratosis, melasma, rosacea, or other significant skin conditions (e.g. skin cancer, active infections, cold sores, open wounds, rashes, burns, inflammation eczema, psoriasis).
• •5\. Predisposition to keloid formation or excessive scarring. 6. Diagnosis of a condition that may compromise the immune system, such as: HIV, lupus, scleroderma, and/or systemic infections.
• •7\. Known sensitivity to light or photosensitizing agents/medications are being taken.
• •8\. Systemic steroids (e.g. prednisone, dexamethasone), which should be rigorously avoided prior to and throughout course of the treatment.
• •9\. Use of retinoids less than 2 weeks prior to or during the study to completion.
• •10\. Individuals undergoing Accutane™ treatment or drugs in a similar class. 11. Having skin that is still recovering from a cosmetic procedure: such as a chemical peel, or mechanical peel, or laser resurfacing within the previous 6 months.
• •12\. Having had Botox injections, neurotoxin injections, or dermal fillers (such as collagen) within the past four months.
• •13\. Sunburn and/or recent sun exposure on the treatment area in the last 2 weeks.
• •14\. Subjects must agree to seek the advice of their medical doctor regarding any known or suspicious skin condition before laser treatment.
• •15\. Any condition or situation that would prevent the subject from safely completing all protocol requirements for participation.
• •16\. Subjects who are unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.